Personalised Health Recommendations to the General Population Through an Integrated AI Guided
- Disease/Condition
- Gastric Cancer,Cancer Prevention,Helicobacter Pylori Infection,Artificial Intelligence
- Drug/Device/Intervention
- Health reccommendations
- Study type
- Interventional
- Intervention type
- behavioral
- Primary sponsor
- Tania Fleitas Kanonnikoff
- Funder
- Fundación para la Investigación del Hospital Clínico de Valencia
- Location
- Valencia, Spain
- Phase
- N/A
- Start date
- Jun 01, 2024
- End date
- Dec 31, 2026
- Enrollment
- 450 participants
Risk of developing Gastric Cancer based on medical records,H. pylori Eradication Therapy Recommendation,GIM risk score assessment using imaging modalities
This clinical study aims to be used to implement and validate the AIDA tool in two phases:
 
 - Phase 1: Risk stratification and personalised recommendations & Model development
 
 - Phase 2: Mechanistic Model (Bioresource) development & testing
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06421324
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06421324 through Pure Global AI's free database. This phase not specified trial is sponsored by Tania Fleitas Kanonnikoff and is currently Not yet recruiting. The study focuses on Gastric Cancer,Cancer Prevention,Helicobacter Pylori Infection,Artificial Intelligence. Target enrollment is 450 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.